Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:BMEA NASDAQ:ELYM NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.92+0.1%$14.79$12.96▼$20.90$333.84M0.8280,527 shs105,805 shsBMEABiomea Fusion$1.39+5.3%$1.43$0.87▼$2.99$100.50M-0.311.32 million shs1.19 million shsELYMEliem Therapeutics$13.08+3.3%$10.73$2.35▼$11.55$389.16M-0.39486,688 shs6.32 million shsUPBUpstream Bio$6.93+2.7%$8.04$5.85▼$33.68$377.13M1.11966,731 shs662,668 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%-0.75%+9.80%+14.05%+1.27%BMEABiomea Fusion0.00%+11.86%-4.35%0.00%-27.07%ELYMEliem Therapeutics0.00%+14.24%+15.34%+86.32%+1,008.47%UPBUpstream Bio0.00%+8.00%-19.26%-23.12%-38.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.92+0.1%$14.79$12.96▼$20.90$333.84M0.8280,527 shs105,805 shsBMEABiomea Fusion$1.39+5.3%$1.43$0.87▼$2.99$100.50M-0.311.32 million shs1.19 million shsELYMEliem Therapeutics$13.08+3.3%$10.73$2.35▼$11.55$389.16M-0.39486,688 shs6.32 million shsUPBUpstream Bio$6.93+2.7%$8.04$5.85▼$33.68$377.13M1.11966,731 shs662,668 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%-0.75%+9.80%+14.05%+1.27%BMEABiomea Fusion0.00%+11.86%-4.35%0.00%-27.07%ELYMEliem Therapeutics0.00%+14.24%+15.34%+86.32%+1,008.47%UPBUpstream Bio0.00%+8.00%-19.26%-23.12%-38.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.50Moderate BuyN/AN/ABMEABiomea Fusion 2.75Moderate Buy$8.50511.51% UpsideELYMEliem Therapeutics 0.00N/AN/AN/AUPBUpstream Bio 2.43Hold$33.17378.60% UpsideCurrent Analyst Ratings BreakdownLatest BMEA, ELYM, UPB, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/12/2026UPBUpstream Bio JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $8.006/3/2026UPBUpstream Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.006/3/2026UPBUpstream Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/18/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2026UPBUpstream Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$51.00 ➝ $50.005/6/2026UPBUpstream Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$213.65M1.56$0.36 per share44.08$22.07 per share0.72BMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/AELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AUPBUpstream Bio$2.85M132.33N/AN/A$6.29 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)BMEABiomea Fusion-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%8/4/2026 (Estimated)ELYMEliem Therapeutics-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/AUPBUpstream Bio-$143.44M-$2.91N/AN/AN/A-4,718.96%-43.82%-42.27%8/5/2026 (Estimated)Latest BMEA, ELYM, UPB, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026UPBUpstream Bio-$0.73-$0.7470-$0.0170-$0.75$1.03 million$1.03 million5/11/2026Q1 2026BMEABiomea Fusion-$0.24-$0.17+$0.07-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.482.46BMEABiomea FusionN/A4.984.98ELYMEliem TherapeuticsN/A60.4160.41UPBUpstream BioN/A23.1423.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%BMEABiomea Fusion96.72%ELYMEliem Therapeutics69.76%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipAMRNAmarin4.21%BMEABiomea Fusion10.60%ELYMEliem Therapeutics4.70%UPBUpstream Bio16.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.97 million20.09 millionOptionableBMEABiomea Fusion5072.30 million64.64 millionOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableUPBUpstream Bio3854.42 million45.46 millionN/ABMEA, ELYM, UPB, and AMRN HeadlinesRecent News About These CompaniesIs Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?June 25, 2026 | insidermonkey.com10 small-cap U.S. healthcare stocks with the weakest momentum gradesJune 24, 2026 | seekingalpha.comIs Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?June 23, 2026 | insidermonkey.comUpstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First PatientsJune 19, 2026 | businesswire.comUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...June 14, 2026 | markets.businessinsider.comUpstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key SymptomsJune 14, 2026 | quiverquant.comQUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026June 14, 2026 | globenewswire.comKBRA Assigns Preliminary Ratings to OBX 2026-AHC2 TrustJune 12, 2026 | businesswire.comUpstream Bio Launches $150 Million At-The-Market ProgramJune 11, 2026 | theglobeandmail.comUpstream Bio Shareholders Elect Directors, Ratify 2026 AuditorJune 10, 2026 | tipranks.comUpstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug ...June 8, 2026 | enidnews.comEUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026June 8, 2026 | globenewswire.comUpstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 3, 2026 | globenewswire.comUpstream Bio: The Reset Is The Opportunity, Initiating At BuyMay 29, 2026 | seekingalpha.comUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at ...May 18, 2026 | markets.businessinsider.comUpstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid AsthmaMay 18, 2026 | quiverquant.comQUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International ConferenceMay 18, 2026 | globenewswire.comLifeSci Capital Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB)May 17, 2026 | theglobeandmail.comUpstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue EstimatesMay 13, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMEA, ELYM, UPB, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$15.92 +0.01 (+0.06%) Closing price 04:00 PM EasternExtended Trading$15.98 +0.05 (+0.35%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Biomea Fusion NASDAQ:BMEA$1.39 +0.07 (+5.30%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Eliem Therapeutics NASDAQ:ELYM$13.08 +0.42 (+3.32%) As of 06/26/2026Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Upstream Bio NASDAQ:UPB$6.93 +0.18 (+2.67%) Closing price 04:00 PM EasternExtended Trading$6.92 0.00 (-0.07%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
